Related Experiment Video
Updated: Mar 17, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Targeting WEE1 Kinase in Cancer
Christopher J Matheson1, Donald S Backos1, Philip Reigan1
1Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 East Montview Boulevard, V20-2102, Aurora, CO 80045, USA.
Abstract:
WEE1 kinase plays a crucial role in the G2-M cell-cycle checkpoint arrest for DNA repair before mitotic entry. Normal cells repair damaged DNA during G1 arrest; however, cancer cells often have a deficient G1-S checkpoint and depend on a functional G2-M checkpoint for DNA repair. WEE1 is expressed at high levels in various cancer types including breast cancers, leukemia, melanoma, and adult and pediatric brain tumors. Many of these cancers are treated with DNA-damaging agents; therefore, targeting WEE1 for inhibition and compromising the G2-M checkpoint presents an opportunity to potentiate therapy. In this review we summarize the current WEE1 inhibitors, the potential for further inhibitor development, and the challenges in the clinic for the WEE1 inhibitor strategy.
Insights
WEE1 kinase is vital for cancer cell DNA repair. Inhibiting WEE1 can enhance cancer treatments, particularly for cancers with faulty DNA repair mechanisms, by disrupting the cell cycle.
Area of Science:
- Oncology
- Molecular Biology
- Cell Cycle Regulation
Background:
- WEE1 kinase is essential for the G2-M cell-cycle checkpoint, enabling DNA repair before mitosis.
- Cancer cells often exhibit a deficient G1-S checkpoint, making them reliant on the G2-M checkpoint for survival.
- Elevated WEE1 expression is observed in numerous cancers, including breast, leukemia, melanoma, and brain tumors.
Purpose of the Study:
- To review current WEE1 inhibitors and their therapeutic potential.
- To explore future directions in WEE1 inhibitor development.
- To discuss clinical challenges associated with WEE1 inhibitor strategies.
Main Methods:
- Literature review of WEE1 kinase function and inhibitors.
- Analysis of WEE1 expression in various cancer types.
- Evaluation of WEE1 inhibition as a potentiating strategy for DNA-damaging agents.
Main Results:
- WEE1 kinase is a critical target for potentiating cancer therapy.
- Inhibiting WEE1 can exploit cancer cells' dependency on the G2-M checkpoint.
- Current WEE1 inhibitors show promise, but clinical application faces challenges.
Conclusions:
- Targeting WEE1 offers a promising strategy to enhance the efficacy of DNA-damaging agents in various cancers.
- Further development of WEE1 inhibitors and overcoming clinical hurdles are crucial for therapeutic success.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:34Inhibition of Cdk Activity